Fraunhofer Institute for Cell Therapy and Immunology IZIAnnual report 2024/25
The Fraunhofer IZI patent portfolio currently consists of 45 patent families (excluding patents held at Fraunhofer IZI-BB), which are available for use in collaborative projects as well as for direct marketing and licensing.
- Novel delivery systems for nucleic acids
- Methods, reagents / antigens and biomarkers for the diagnosis of various infections and other diseases for human and veterinary medicine
- New treatment methods for cancer and other diseases
- New method for the prevention of graft-versus-host disease (GvHD)
- Mineral compounds for prevention / therapy of kidney and intestinal diseases
- RNA biomarkers for the prognosis of certain cancers
- Methods, biomarkers and device components for point-of-care diagnostics of infectious agents and liver / kidney diseases
- Drug / vaccine candidates for infectious diseases and amyloidoses
- New viral vectors including optimized AAV vectors for gene modification of immune cells
- Inactivation of pathogens in the context of vaccine production
- Novel ATMPs and methods for their optimization
- Technologies for the rapid identification and optimization of chimeric antigen receptors (CARs) for cell and gene therapy
- Epitopes from food relevant for the development of allergies and corresponding antibodies as a basis for allergy test developments
- Technologies for microfluidic systems
- Dialysis methods and novel components of dialysis systems
- Technical solution for the combination of amplification methods and LTF-based detection in one vessel for novel rapid infection tests